|Mr. Andrew David William Newland||Founder, CEO & Executive Director||264k||N/A||1962|
|Mr. Ian Francis Griffiths||CFO, Finance Director, Company Secretary & Executive Director||164k||N/A||1965|
|Mr. Martin Cooke||Director of Operations & Regulatory Affairs||N/A||N/A||1969|
|Dr. Karen Miller Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Andrew John Holder||Head of Investor Relations||N/A||N/A||1968|
|Ms. Anne-Sophie Pailhes-Jimenez||Head of R&D and Senior Director||N/A||N/A||N/A|
|Mr. Brett Swansiger||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Nick Claxton||Senior Vice President of Commercial Operations||N/A||N/A||N/A|
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.
ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.